Epidermal Growth Factor Receptor Inhibitors: A Review of Cutaneous Adverse Events and Management

Table 1

Summery of oral antibiotic in the prevention of EGFRI-induced skin toxicity.

Author; Year	EGFRI agent	Patients; (𝑛)	Antibiotic	Objective	Results	Quality of life
Scope et al. 2007 [35]	Cetuximab	48	Minocycline	To decrease or prevent skin toxicity	Lower facial lesion count with minocycline (𝑃 value 0.05)	Lower itch severity
Jatoi et al. 2008 [36]	Multiple	61	Tetracycline	To prevent or decrease grade ≥2 rash	No difference in rash incidence (70% versus 76% 𝑃 value 0.61); Significant lower grade ≥2 rash (17% versus 55%, 𝑃 value 0.04)	Less burning and irritation with tetracycline
Laouture et al. 2010 [37]	Panitumumab	95	Doxycycline; (plus skin moisturizer, sunscreen, and topical steroid) as prophylactic regimen	To decrease grade ≥2 toxicity	Lower incidence of grade ≥2 toxicity in prophylactic regimen (29 versus 62%, OR, 0.3; 95% CL, 0.1 to 0.6)	More improvement of DLQI in prophylactic group
Deplaque et al. 2010 [38].	Erlotinib	147	Doxycycline	To prevent or decrease severity of folliculitis	No difference in folliculitis incidence (68% versus 82%, 𝑃 value = 0.055).; Significant decrease in severity 𝑃<0.001; Lower incidence of grade ≥2 folliculitis in doxycycline arm (39% versus 82%)	NA

All are RCTs.
DLQI: Dermatologic Life Quality Index. NA: not assessed.